The SAVE regimen achieved an 86% ORR in newly diagnosed AML, with high MRD-negative rates, especially in NPM1 mutations or KMT2A rearrangements. Significant myelosuppression and infectious ...

Jones anchored her discussion in a core philosophy for veterinary oncology: "one size does not fit all.” According to Jones, ...

An update from bioAffinity Technologies, Inc. ( ($BIAF) ) is now available. On December 3, 2025, bioAffinity Technologies announced that it will ...

The Global MRD Testing Market is expanding due to rising cancer and hematological malignancy rates and advances in diagnostic ...

ACS--bioAffinity Technologies, Inc. (Nasdaq: BIAF; BIAFW), a biotechnology company advancing noninvasive diagnostics for lung cancer and other lung diseases, today announced that Chief Medical Officer ...

The IDEXX Cancer Dx is a new blood-based screening/diagnostic panel aimed at detecting canine lymphoma from serum or whole ...

In this edition of the biotech bi-weekly, we highlight the latest exciting product launches, partnerships and company events.

Key points A healthy 34-year-old man presented to his local walk-in clinic with dysuria and dark (tea-coloured) urine. He did not have any previous episodes of dark urine and denied any other ...

Key points A 62-year-old man with hypertension and chronic renal disease presented to an emergency department with abdominal pain and chills. His vital signs were normal except for high blood pressure ...

MRD negativity post-chemotherapy strongly predicts improved overall survival in AML, with a significant reduction in mortality risk. The study suggests MRD could serve as an earlier surrogate endpoint ...

Over the past six decades, anti-thrombotic drug therapies have undergone a revolution, leading to major improvements in ...

TUS+VEN+AZA triplet frontline therapy demonstrates high rates of efficacy and MRD-negative remissions in newly diagnosed AML patients with ...